PMID- 19941460
OWN - NLM
STAT- MEDLINE
DCOM- 20101103
LR  - 20220311
IS  - 2212-3946 (Electronic)
IS  - 1574-888X (Linking)
VI  - 5
IP  - 2
DP  - 2010 Jun
TI  - Adipose tissue derived stem cells secretome: soluble factors and their roles in 
      regenerative medicine.
PG  - 103-10
AB  - Stem cells have been long looked at as possible therapeutic vehicles for 
      different health related problems. Among the different existing stem cell 
      populations, Adipose- derived Stem Cells (ASCs) have been gathering attention in 
      the last 10 years. When compared to other stem cells populations and sources, 
      ASCs can be easily isolated while providing simultaneously higher yields upon the 
      processing of adipose tissue. Similar to other stem cell populations, it was 
      initially thought that the main potential of ASCs for regenerative medicine 
      approaches was intimately related to their differentiation capability. Although 
      this is true, there has been an increasing body of literature describing the 
      trophic effects of ASCs on the protection, survival and differentiation of 
      variety of endogenous cells/tissues. Moreover, they have also shown to possess an 
      immunomodulatory character. This effect is closely related to the ASCs' secretome 
      and the soluble factors found within it. Molecules such as hepatocyte growth 
      factor (HGF), granulocyte and macrophage colony stimulating factors, interleukins 
      (ILs) 6, 7, 8 and 11, tumor necrosis factor-alpha (TNF-alpha), vascular 
      endothelial growth factor (VEGF), brain derived neurotrophic factor (BDNF), nerve 
      growth factor (NGF), adipokines and others have been identified within the ASCs' 
      secretome. Due to its importance regarding future applications for the field of 
      regenerative medicine, we aim, in the present review, to make a comprehensive 
      analysis of the literature relating to the ASCs' secretome and its relevance to 
      the immune and central nervous system, vascularization and cardiac regeneration. 
      The concluding section will highlight some of the major challenges that remain 
      before ASCs can be used for future clinical applications.
FAU - Salgado, Antonio J Braga Osorio Gomes
AU  - Salgado AJ
AD  - Life and Health Sciences Research Institute (ICVS), School of Health Sciences, 
      University of Minho, Braga, Portugal. asalgado@ecsaude.uminho.pt
FAU - Reis, RuI L Goncalves
AU  - Reis RL
FAU - Sousa, Nuno Jorge Carvalho
AU  - Sousa NJ
FAU - Gimble, Jeffrey M
AU  - Gimble JM
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Curr Stem Cell Res Ther
JT  - Current stem cell research & therapy
JID - 101272517
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Cytokines)
RN  - 0 (HGF protein, human)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 143011-72-7 (Granulocyte Colony-Stimulating Factor)
RN  - 67256-21-7 (Hepatocyte Growth Factor)
RN  - 81627-83-0 (Macrophage Colony-Stimulating Factor)
RN  - 9061-61-4 (Nerve Growth Factor)
SB  - IM
MH  - Adipose Tissue/*pathology
MH  - Brain-Derived Neurotrophic Factor/metabolism
MH  - Cytokines/immunology/metabolism
MH  - Granulocyte Colony-Stimulating Factor/metabolism
MH  - *Guided Tissue Regeneration
MH  - Heart/physiology
MH  - Hepatocyte Growth Factor/metabolism
MH  - Humans
MH  - Induced Pluripotent Stem Cells/immunology/*metabolism/pathology
MH  - Macrophage Colony-Stimulating Factor/metabolism
MH  - Neovascularization, Physiologic
MH  - Nerve Growth Factor/metabolism
MH  - Regenerative Medicine
MH  - Vascular Endothelial Growth Factor A/metabolism
RF  - 77
EDAT- 2009/11/28 06:00
MHDA- 2010/11/04 06:00
CRDT- 2009/11/28 06:00
PHST- 2009/06/12 00:00 [received]
PHST- 2009/07/09 00:00 [accepted]
PHST- 2009/11/28 06:00 [entrez]
PHST- 2009/11/28 06:00 [pubmed]
PHST- 2010/11/04 06:00 [medline]
AID - ABSTRACT # 21 [pii]
AID - 10.2174/157488810791268564 [doi]
PST - ppublish
SO  - Curr Stem Cell Res Ther. 2010 Jun;5(2):103-10. doi: 10.2174/157488810791268564.